4.5 Article

Recurrent Fusions Between YAP1 and KMT2A in Morphologically Distinct Neoplasms Within the Spectrum of Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma

Journal

AMERICAN JOURNAL OF SURGICAL PATHOLOGY
Volume 44, Issue 5, Pages 594-606

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PAS.0000000000001423

Keywords

YAP1; KMT2A; PRRX1; KMT2D; sclerosing epithelioid fibrosarcoma; low grade fibromyxoid sarcoma; fusion; sarcoma; immunohistochemistry

Funding

  1. Swedish Cancer Society [CAN2017/269]
  2. Swedish Childhood Cancer Fund [PR2017-0019]
  3. Region Skane

Ask authors/readers for more resources

Sclerosing epithelioid fibrosarcoma (SEF) is an aggressive soft tissue sarcoma. In the majority of cases, there is overexpression of MUC4, and most cases show EWSR1-CREB3L1 gene fusions. A subset of SEF displays composite histologic features of SEF and low-grade fibromyxoid sarcoma (LGFMS). These hybrid tumors are more likely to harbor the FUS-CREB3L2 fusion, which is also seen in most LGFMS. We, here, characterize a series of 8 soft tissue neoplasms with morphologic features highly overlapping with LGFMS and SEF but lacking MUC4 expression and EWSR1/FUS-CREB3L gene fusions. Seven tumors showed fusions of the YAP1 and KMT2A genes, and 1 had a fusion of PRRX1 and KMT2D; all but 1 case displayed reciprocal gene fusions. At gene expression profiling, YAP1 and KMT2A/PRRX1 and KMT2D tumors were distinct from LGFMS/SEF. The patients were 4 female individuals and 4 male individuals aged 11 to 91 years. Tumors with known locations were in the lower extremity (5), trunk (2), and upper extremity (1); 3 originated in acral locations. Tumor size ranged from 2.5 to 13 cm. Proportions of SEF-like and LGFMS-like areas varied considerably among tumors. All tumors that showed infiltrative growth and mitotic figures per 10 HPFs ranged from 0 to 18. Tumor necrosis was present in 1 case. Follow-up was available for 5 patients (11 to 321 mo), 2 of whom developed local recurrences, and 1 died of metastatic disease. The clinical behavior of these soft tissue sarcomas remains to be further delineated in larger series with extended follow-up; however, our limited clinical data indicate that they are potentially aggressive.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pathology

Aberrant receptor tyrosine kinase signaling in lipofibromatosis: a clinicopathological and molecular genetic study of 20 cases

Alyaa Al-Ibraheemi, Andrew L. Folpe, Antonio R. Perez-Atayde, Kyle Perry, Jakob Hofvander, Elsa Arbajian, Linda Magnusson, Jenny Nilsson, Fredrik Mertens

MODERN PATHOLOGY (2019)

Article Cell Biology

Gene fusion involving the insulin-like growth factor 1 receptor in an ALK-negative inflammatory myofibroblastic tumour

Giuseppe Piarulli, Florian Puls, Bo Wangberg, Henrik Fagman, Magnus Hansson, Jenny Nilsson, Elsa Arbajian, Fredrik Mertens

HISTOPATHOLOGY (2019)

Article Pathology

Lobular neoplasia and invasive lobular breast cancer: Inter-observer agreement for histological grading and subclassification

Nora Schaumanna, Mieke Raap, Laura Hinze, Luisa Rieger, Christian M. Schurch, Wiebke Antonopoulos, Stefanie Avril, Till Krech, Maximilian Daemmrich, Gian Kayser, Florian Puls, Florian Laenger, Marianne Tinguely, Hans Kreipe, Matthias Christgen

PATHOLOGY RESEARCH AND PRACTICE (2019)

Article Oncology

Deep sequencing of myxoinflammatory fibroblastic sarcoma

Elsa Arbajian, Jakob Hofvander, Linda Magnusson, Fredrik Mertens

GENES CHROMOSOMES & CANCER (2020)

Article Pathology

PHF1 fusions cause distinct gene expression and chromatin accessibility profiles in ossifying fibromyxoid tumors and mesenchymal cells

Jakob Hofvander, Vickie Y. Jo, Christopher D. M. Fletcher, Florian Puls, Uta Flucke, Jenny Nilsson, Linda Magnusson, Fredrik Mertens

MODERN PATHOLOGY (2020)

Article Oncology

Genomic and transcriptomic features of dermatofibrosarcoma protuberans: Unusual chromosomal origin of the COL1A1-PDGFB fusion gene and synergistic effects of amplified regions in tumor development

Jan Koster, Elsa Arbajian, Bjorn Viklund, Anders Isaksson, Jakob Hofvander, Felix Haglund, Henrik Bauer, Linda Magnusson, Nils Mandahl, Fredrik Mertens

CANCER GENETICS (2020)

Article Oncology

A gene expression-based single sample predictor of lung adenocarcinoma molecular subtype and prognosis

Helena Liljedahl, Anna Karlsson, Gudrun N. Oskarsdottir, Annette Salomonsson, Hans Brunnstrom, Gigja Erlingsdottir, Mats Jonsson, Sofi Isaksson, Elsa Arbajian, Cristian Ortiz-Villalon, Aziz Hussein, Bengt Bergman, Anders Vikstrom, Nastaran Monsef, Eva Branden, Hirsh Koyi, Luigi de Petris, Annika Patthey, Annelie F. Behndig, Mikael Johansson, Maria Planck, Johan Staaf

Summary: Gene expression-based single sample predictors can provide molecular subtype and independent prognostic information in early-stage lung adenocarcinoma. These predictors may overcome critical limitations in the applicability of gene signatures in lung cancer.

INTERNATIONAL JOURNAL OF CANCER (2021)

Article Oncology

Methylation Patterns and Chromatin Accessibility in Neuroendocrine Lung Cancer

Elsa Arbajian, Mattias Aine, Anna Karlsson, Johan Vallon-Christersson, Hans Brunnstrom, Josef Davidsson, Sofie Mohlin, Maria Planck, Johan Staaf

CANCERS (2020)

Article Pathology

Poorly differentiated chordoma showing loss of SMARCB1/INI1: Clinicopathological and radiological spectrum of nine cases, including uncommon features of a relatively under-recognized entity

Bharat Rekhi, Michael Michal, Fatma Bilge Ergen, Paromita Roy, Florian Puls, Hans Kristian Haugland, Figen Soylemezoglu, Kemal Kosemehmetoglu

Summary: Poorly differentiated chordomas are a newly recognized entity that displays a spectrum of features and aggressive outcomes. Timely diagnosis requires critical analysis of radiological and histopathological features, including necessary immunostains such as brachyury and SMARCB1/INI1. These tumors typically show loss of SMARCB1/INI1 immunostaining and homozygous deletion of the INI1/SMARCB1 gene, and are associated with a lower index of suspicion for diagnosis.

ANNALS OF DIAGNOSTIC PATHOLOGY (2021)

Article Oncology

Molecular characteristics of lung adenocarcinoma with respect to patient age at diagnosis

Johan Staaf, Mattias Aine, Deborah F. Nacer, Maria Planck, Elsa Arbajian

Summary: This study investigated the differences in clinical characteristics, molecular alterations, and molecular phenotypes between patient populations with early-stage lung adenocarcinoma with respect to age at diagnosis. It was found that younger patients were more likely to harbor certain driver mutations. Age was also associated with certain mutational signatures, but did not affect transcriptional, copy number, or epigenetic variation in the tumors.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Oncology

Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms

Janne Lehtio, Taner Arslan, Ioannis Siavelis, Yanbo Pan, Fabio Socciarelli, Olena Berkovska, Husen M. Umer, Georgios Mermelekas, Mohammad Pirmoradian, Mats Jonsson, Hans Brunnstrom, Odd Terje Brustugun, Krishna Pinganksha Purohit, Richard Cunningham, Hassan Foroughi Asl, Sofi Isaksson, Elsa Arbajian, Mattias Aine, Anna Karlsson, Marija Kotevskaz, Carsten Gram Hansen, Vilde Drageset Haakensen, Aslaug Helland, David Tamborero, Henrik J. Johansson, Rui M. Branca, Maria Planckz, Johan Staaf, Lukas M. Orre

Summary: Researchers conducted a proteogenomic analysis of non-small cell lung cancer, identifying molecular subtypes with distinct immune-evasion mechanisms and therapeutic targets. They validated their classification method in separate clinical cohorts, discovering high neoantigen burden linked to global hypomethylation and immune evasion mechanisms associated with STK11 mutation-dependent HNF1A activation and FGL1 expression. Furthermore, they developed a data-independent acquisition mass-spectrometry-based NSCLC subtype classification method, validating it in independent cohorts and demonstrating clinical utility.

NATURE CANCER (2021)

Article Oncology

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma

Sara Bjursten, Christoffer Vannas, Stefan Filges, Florian Puls, Ankur Pandita, Henrik Fagman, Anders Stahlberg, Max Levin

CASE REPORTS IN ONCOLOGY (2019)

No Data Available